購(gòu)物車(chē) 
-
凈司他丁
- names：
Zinostatin
- CAS號(hào)：
79633-18-4
MDL Number： - MF(分子式)： C35H35NO12 MW(分子量)： 661.66
- EINECS: Reaxys Number:
- Pubchem ID: Brand:BIOFOUNT
| 貨品編碼 | 規(guī)格 | 純度 | 價(jià)格 (￥) | 現(xiàn)價(jià)(￥) | 特價(jià)(￥) | 庫(kù)存描述 | 數(shù)量 | 總計(jì) (￥) |
|---|
- 大包裝詢價(jià) 提供各種包裝，敬請(qǐng)垂詢
- 收藏商品 商品點(diǎn)評(píng) 加入購(gòu)物車(chē) 立即購(gòu)買(mǎi)
| 中文別名 | 凈司他丁; 新制癌菌素 |
| 英文別名 | Zinostatin; Neocarcinostatin |
| CAS號(hào) | 79633-18-4 |
| Inchi | InChI=1S/C35H35NO12/c1-16-12-19(42-4)14-22-20(16)8-9-23(37)27(22)32(40)45-24-13-18-10-11-35(26-15-43-34(41)46-26)25(48-35)7-5-6-21(18)31(24)47-33-28(36-3)30(39)29(38)17(2)44-33/h8-9,12-14,17,21,24-26,28-31,33,36-39H,6,15H2,1-4H3/t17-,21?,24-,25?,26?,28-,29+,30-,31-,33-,35+/m1/s1 |
| InchiKey | BLXZMHNVKCEIJX-LTZUVELHSA-N |
| 分子式 Formula | C35H35NO12 |
| 分子量 Molecular Weight | 661.66 |
| 溶解度Solubility | |
| 性狀 | Solid powder |
| 儲(chǔ)藏條件 Storage conditions | Dry, dark and store at 0-4℃ for short term (days to weeks) or -20℃ for long term (Store correctly 2-3years). |
| 產(chǎn)品說(shuō)明 | Zinostatin(CAS:2598369):僅限應(yīng)用于工業(yè)或者科學(xué)研究過(guò)程中非醫(yī)療目的，不應(yīng)用于人類(lèi)或動(dòng)物的臨床診斷以及治過(guò)程療，該產(chǎn)品非藥用，非食用。 |
| Introduction | Zinostatin is a cytotoxic enediyne that alkylates DNA and RNA like mitomycin does. It has antineoplastic and antibiotic properties. It is isolated from the bacterium Streptomyces carzinostaticus. It may be active against hepatocellular carcinoma. |
| Application1 | |
| Application2 | |
| Application3 |
| [1]Nichols JW, Bae YH. EPR: Evidence and fallacy. J Control Release. 2014 Sep 28;190:451-64. doi: 10.1016/j.jconrel.2014.03.057. Epub 2014 Apr 30. Review. PubMed PMID: 24794900. |
| [2]Ishii H, Furuse J, Nagase M, Maru Y, Yoshino M, Hayashi T. A phase I study of hepatic arterial infusion chemotherapy with zinostatin stimalamer alone for hepatocellular carcinoma. Jpn J Clin Oncol. 2003 Nov;33(11):570-3. PubMed PMID: 14711981. |
| [3] Okusaka T, Okada S, Ueno H, Ikeda M, Iwata R, Furukawa H, Takayasu K, Moriyama N, Sato T, Sato K. Transcatheter arterial embolization with zinostatin stimalamer for hepatocellular carcinoma. Oncology. 2002;62(3):228-33. PubMed PMID: 12065870. |
| [4] Toge T, Jinushi K, Sawamura A, Matsuki K. [Study on the intra-tumor tissue concentration of zinostatin stimalamer in the liver following intra-arterial injection of zinostatin stimalamer (YM881) suspension]. Gan To Kagaku Ryoho. 1991 Aug;18(10):1677-80. Japanese. PubMed PMID: 1651687. |
| [5] Sansiaume-Dagousset E, Urvoas A, Chelly K, Ghattas W, Maréchal JD, Mahy JP, Ricoux R. Neocarzinostatin-based hybrid biocatalysts for oxidation reactions. Dalton Trans. 2014 Jun 14;43(22):8344-54. doi: 10.1039/c4dt00151f. PubMed PMID: 24728274. |
6: Hirashima N, Sakakibara K, Itazu I, Hirai T, Nemoto A, Matsuura H, Kumada K, Nojiri O, Kano H. Zinostatin stimalamer-transcatheter arterial embolization for hepatocellular carcinoma: a comparison with lipiodol-transcatheter arterial embolization. Semin Oncol. 1997 Apr;24(2 Suppl 6):S6-91-S6-96. PubMed PMID: 9151922.7: Urvoas A, Ghattas W, Maréchal JD, Avenier F, Bellande F, Mao W, Ricoux R, Mahy JP. Neocarzinostatin-based hybrid biocatalysts with a RNase like activity. Bioorg Med Chem. 2014 Oct 15;22(20):5678-86. doi: 10.1016/j.bmc.2014.05.063. Epub 2014 Jun 14. PubMed PMID: 24984934.8: Fukuhara K, Suzuki M, Unno M, Rikiyama T, Sakamoto N, Takeuchi H, Uchiyama T, Yamaki T, Iwasashi H, Kodama H, Matsuno S. [An anaphylactic shock case after hepatic arterial infusion of zinostatin stimalamer suspension improved by anti-histaminics]. Gan To Kagaku Ryoho. 1997 Jun;24(8):1023-6. Japanese. PubMed PMID: 9212813.9: Tianqin G, Chunlei C, Jingjing W. Synergistic Anti-glioma Effects in Vitro and in Vivo of Enediyne Antibiotic Neocarzinostatin and Paclitaxel via Enhanced Growth Delay and Apoptosis-Induction. Biol Pharm Bull. 2016 Oct 1;39(10):1623-1630. Epub 2016 Jul 14. PubMed PMID: 27431785.10: Issell BF, Ginsberg SJ, Comis RL. Zinostatin and doxorubicin. A combination phase I study. Cancer Clin Trials. 1981 Fall;4(3):323-6. PubMed PMID: 6269771.1
對(duì)不起，暫無(wú)產(chǎn)品評(píng)價(jià)！
MSDS
SDS 1.0 中文
展開(kāi)
SDS 1.0 英文
展開(kāi)
- 相關(guān)產(chǎn)品
-
< >
- 推薦產(chǎn)品
-
< >
- 最新產(chǎn)品
-
< >
新聞
胞爬片免疫組化染色.png)
怎么做細(xì)胞爬片免疫組化染色實(shí)驗(yàn)
細(xì)胞爬片免疫組化染色，是通過(guò)細(xì)胞爬片是讓玻片浸在細(xì)胞培養(yǎng)基內(nèi)，細(xì)胞在玻片上生長(zhǎng)，主要用于組織學(xué)，免疫組織化學(xué)...
2020/7/20 22:04:33
提取病毒RNA的實(shí)驗(yàn)方法
提取病毒RNA方法分別有：異硫氰酸胍的提取病毒RNA方法、TRIzol LS提取法、Trizol法提取法等等...
2020/7/22 20:29:26
9月開(kāi)學(xué)季——助研新學(xué)期 范德送好禮
2025/8/28 15:30:55
Waxfilm 實(shí)驗(yàn)室封口膜：技術(shù)與國(guó)際市場(chǎng)的雙重突破
在實(shí)驗(yàn)室耗材領(lǐng)域，封口膜是保障實(shí)驗(yàn)準(zhǔn)確性與穩(wěn)定性的關(guān)鍵產(chǎn)品之一。近年來(lái)，Waxfilm?實(shí)驗(yàn)室封口膜憑借其卓...
2025/5/13 13:03:40
Waxfilm實(shí)驗(yàn)室封口膜的5大突破
Waxfilm實(shí)驗(yàn)室封口膜作為生物功能膜領(lǐng)域的國(guó)產(chǎn)技術(shù)突破和品牌突破，是生物領(lǐng)域中國(guó)技術(shù)發(fā)展的縮影。
2025/5/6 17:02:07
各種微流控芯片鍵合方法的優(yōu)缺點(diǎn)
微流控芯片鍵合：目前主要有激光焊接、熱壓鍵合、膠鍵合、超音波焊接，每種方法都有各自的優(yōu)缺點(diǎn)。本文主要介紹聚酯...
2023/7/28 10:43:09
材料.jpg)
新一代微流控鍵合解決方案
微流控鍵合解決方案：微流控芯片制造的一個(gè)重要環(huán)節(jié)，也是最容易被忽視的--芯片鍵合。其中一個(gè)重要因素是：微流控...
2023/7/27 12:44:28
驗(yàn)動(dòng)物圖.png)
熒光素鉀鹽使用說(shuō)明
D-熒光素鉀鹽（K+）設(shè)計(jì)用于體外和體內(nèi)生物發(fā)光測(cè)定。D-熒光素的質(zhì)量和純度對(duì)于獲得良好和可重復(fù)的結(jié)果至關(guān)重...
2023/7/20 11:05:11
如何選BSA（牛血清白蛋白）
如何選BSA（牛血清白蛋白）：牛血清白蛋白（BSA）有多種形式，如何選擇適合自己的牛血清白蛋白（BSA）是一...
2023/2/14 13:09:18
牛血清白蛋白（BSA）常見(jiàn)問(wèn)題
牛血清白蛋白（BSA）常見(jiàn)問(wèn)題:牛血清白蛋白（BSA）在實(shí)驗(yàn)室中是通用的，可用于蛋白質(zhì)印跡、細(xì)胞組織培養(yǎng)、P...
2022/10/19 9:39:51
